Antroquinonol - Golden Biotechnology Corporation

Drug Profile

Antroquinonol - Golden Biotechnology Corporation

Alternative Names: Hocena

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Golden Biotechnology Corporation
  • Developer China Sky One Medical; Golden Biotechnology Corporation; Queensland University of Technology
  • Class Alkenes; Antidementias; Antineoplastics; Cyclohexenes; Ketones; Small molecules
  • Mechanism of Action Epidermal growth factor receptor modulators; Mitogen-activated protein kinase modulators; Proto oncogene protein c akt modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma; Acute myeloid leukaemia; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Hyperlipidaemia; Non-small cell lung cancer; Pancreatic cancer
  • Preclinical Alzheimer's disease
  • No development reported Cancer

Most Recent Events

  • 01 Dec 2017 Golden Biotechnology receives patent for methods and compositions for treatment of Neurodegenerative disorders in USA
  • 01 Dec 2017 Phase-I/II clinical trials in Pancreatic cancer (First-line therapy, Late-stage disease, Metastatic disease, Combination therapy) in USA (PO) (NCT03310632)
  • 24 Oct 2017 Golden Biotechnology Corporation plans a phase I/II trial for Pancreatic Cancer (First-line therapy, Metastatic disease, Combination therapy), in November 2017 (NCT03310632)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top